Prof. Dr. Mehmet Sinan DAL

1. Association between pre-transplant CONUT score and pneumonia risk after allogeneic stem cell transplantation in acute leukemia

YENİBERTİZ D., Akkurt E. S., Düvenci̇ Bi̇rben Ö., Darçin T., Türk Ü., Dal M. S.

BMC Pulmonary Medicine , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

2. Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

Matasar M., Li Z., Vassilakopoulos T. P., Sancho J., Viardot A., McMillan A., et al.

Journal of Clinical Oncology , cilt.44, 2026 (SCI-Expanded, Scopus)

3. Filamentous fungi, and their antifungal susceptibilities, isolated from patients at an oncology hospital in Turkey Hongos filamentosos aislados de pacientes en un hospital oncológico en Turquía y sus sensibilidades antifúngicas

Güreser A. S., Karabıçak N., Süzük Yıldız S., Ölmez M. E., MUMCUOĞLU İ., İnan N., et al.

Revista Iberoamericana de Micologia , cilt.43, sa.2, ss.36-39, 2026 (SCI-Expanded, Scopus)

4. Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era

Seçilmiş S., Aslan Candır B., Hatipoğlu U., Seyhan M., Uncu Ulu B., YİĞENOĞLU T. N., et al.

Pharmaceuticals , cilt.19, sa.4, 2026 (SCI-Expanded, Scopus)

5. Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey

Bakırtaş M., BERBER İ., Hindilerden İ. Y., Dal M. S., İzmir Güner Ş., Uysal A., et al.

Journal of Clinical Medicine , cilt.15, sa.5, 2026 (SCI-Expanded, Scopus)

6. Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patients

YILMAZ U., Dal M. S., Ulaş T., Ateşoğlu E. B., Keklik Karadağ F., Mengüç M. U., et al.

Cancer , cilt.132, sa.1, 2026 (SCI-Expanded, Scopus)

7. Evaluating pre-transplant nutritional indices as predictors of pneumonia and mortality in multiple myeloma patients post-autologous stem cell transplantation

Duvenci Birben O., YENİBERTİZ D., Akkurt E. S., Darcın T., Kes Y. D., DAL M. S.

BMC Pulmonary Medicine , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

8. Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel

Beksaç M., ŞAHLI E., Rabea A., Saydam G., Tombak A., Alhuraiji A., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.25, sa.10, 2025 (SCI-Expanded, Scopus)

9. Solitary Plasmacytomas: Current Status in 2025

Hatipoğlu U., Seyhan M., Ulas T., DAL M. S., ALTUNTAŞ F.

Hematology Reports , cilt.17, sa.4, 2025 (ESCI, Scopus)

10. The role of heparin in autologous stem cell mobilization in patients with multiple myeloma

SARICI A., ERKURT M. A., YILMAZ S., Demircioglu S., BERBER İ., BAŞTÜRK A., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

11. Fresh and cryopreserved stem cell transplantation in myeloma patients: Does it make a difference on transplant outcomes?

ERKURT M. A., YILMAZ S., NAMDAROĞLU S., Demircioglu S., SARICI A., Cirik S., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

12. The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomes

Aslan Candir B., Okumus N., Hindilerden I. Y., ERKURT M. A., NAMDAROĞLU S., Merter M., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

13. Is there a relationship between stem cell yield obtained from healthy donors and healthy donors’ blood type?

Katircilar Y., Sahin A., Aydin M. S., Erer K., ERKURT M. A., NAMDAROĞLU S., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

14. Does body mass index affect stem cell yield in healthy donors?

YILMAZ S., Okumus N., Seyhan M., Sahin R., Korkmaz G., ERKURT M. A., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

15. The impact of second allogeneic hematopoietic stem cell transplantation as salvage therapy for hematologic diseases after a first allogeneic transplantation

BATGİ H., Zorlu T., ERKURT M. A., UZAY A., Hindilerden I. Y., Pepeler M. S., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

16. The comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma

Karakus A., Hatipoglu U., Katircilar Y., ERKURT M. A., YILMAZ S., Cagliyan G. A., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

17. Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma

Zorlu T., Kayer M. A., Okumus N., Ulaş T., DAL M. S., ALTUNTAŞ F.

Diagnostics , cilt.15, sa.13, 2025 (SCI-Expanded, Scopus)

18. Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias

Karakus A., TOPTAŞ T., DAL M. S., Durdu A., Hatipoglu U., Kayer M. A., et al.

Bone Marrow Transplantation , cilt.60, sa.6, ss.864-872, 2025 (SCI-Expanded, Scopus)

19. Extranodal Nasal-Type NK/T-Cell Lymphoma Treatment: Analysis from a Multicenter Study

Sahin D., Soyer N., Yeral M., NAMDAROĞLU S., HİNDİLERDEN F., Aydogdu I., et al.

Nigerian Journal of Clinical Practice , cilt.28, sa.5, ss.602-607, 2025 (SCI-Expanded, Scopus)

20. The role of ruxolitinib in the management of acute GVHD

NAMDAROĞLU S., Hidayet E., Aydin M. S., ERKURT M. A., BERBER İ., Cinar O. E., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

21. Is there a relationship between vitamin D levels and graft versus host disease?

YİĞENOĞLU T. N., Ulu B. U., NAMDAROĞLU S., ERKURT M. A., Sahin R., Okumus N., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

22. Are mesenchymal stem cells still effective in acute GvHD management?

Ulu B. U., Hindilerden I. Y., YİĞENOĞLU T. N., Tiryaki T. O., ERKURT M. A., Korkmaz G., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

23. Effectiveness of ibrutinib in the management of chronic GVHD

ERKURT M. A., SARICI A., Sahin A., BERBER İ., Korkmaz G., KUKU İ., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

24. Efficacy of Ruxolitinib in the management of chronic GVHD

Giden A. O., ERKURT M. A., Hindilerden I. Y., Hidayet E., BERBER İ., Tiryaki T. O., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

25. What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?

Ulas T., NAMDAROĞLU S., Hindilerden I. Y., ERKURT M. A., Erer K., YİĞENOĞLU T. N., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

26. What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?

YİĞENOĞLU T. N., ERKURT M. A., DAĞDAŞ S., Ulu B. U., KUKU İ., Durdu A., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

27. A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting Therapies Nüks/Dirençli Büyük B-Hücreli Lenfomanın Tedavisinde Katedilecek Çok Yol Var: Bispesifik ve CAR-T Erişimi Olmayan Hastalarda Gerçek Yaşam Sonuçları

YILMAZ U., DAL M. S., Ulaş T., Ateşoğlu E. B., Karadağ F. K., Mengüç M. U., et al.

Turkish Journal of Hematology , cilt.42, sa.4, ss.265-280, 2025 (SCI-Expanded, Scopus, TRDizin)

28. Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization

Bakırtaş M., Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Kılınç A., Darçın T., et al.

Hematology, Transfusion and Cell Therapy , cilt.47, sa.1, 2025 (ESCI, Scopus)

29. Role of WT1 in Measurable Residual Disease Follow-Up in the Post Allogeneic Stem Cell Transplant Setting

NAMDAROĞLU S., BAŞCI S., Aslan Candır B., Yaman S., YİĞENOĞLU T. N., Bahsi T., et al.

Journal of Clinical Medicine , cilt.13, sa.17, 2024 (SCI-Expanded, Scopus)

30. Is an earlier strategy for harvesting peripheral blood stem cells in healthy allogeneic donors feasible?

Yaman S., Bozan E., Seçilmiş S., Candır B. A., Kılınç A., BAŞCI S., et al.

Transfusion and Apheresis Science , cilt.63, sa.4, 2024 (SCI-Expanded, Scopus)

31. Evaluation of oral manifestations and head and neck lymphadenopathy in newly diagnosed acute leukemia patients

PAMUKÇU U., DAL M. S., Yaman S., Aslan Candır B., Bozan E., Secilmis S., et al.

Special Care in Dentistry , cilt.44, sa.3, ss.911-918, 2024 (ESCI, Scopus)

32. Is neutropenic fever an obstacle to effective stem cell harvesting?

BAŞCI S., Bozan E., Yaman S., Ulu B. U., Bakırtaş M., YİĞENOĞLU T. N., et al.

Asian Journal of Transfusion Science , cilt.18, sa.1, ss.21-26, 2024 (ESCI, Scopus)

33. Is Ruxolitinib an Effective and Safe Therapy for Chronic Myeloproliferative Diseases? Ruksolitinib Kronik Miyeloproliferatif Hastalık için Etkili ve Güvenli Bir Tedavi mi?

Candır B. A., Seçilmiş S., Bozan E., Yaman S., YİĞENOĞLU T. N., KIZIL ÇAKAR M., et al.

Acta Haematologica Oncologica Turcica , cilt.57, sa.1, ss.1-7, 2024 (Scopus, TRDizin)

34. Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis Proteazom İnhibitörleri ve İmmünomodülatör Ajanlar Çağında Primer Plazma Hücreli Lösemili Hastaların Sağkalım Sonuçları: Gerçek Yaşam Verilerinden Çok Merkezli Bir Analiz

ATAŞ Ü., SALİM O., ILTAR U., YÜCEL O. K., Eroğlu A. H. K., Aslan V., et al.

Turkish Journal of Hematology , cilt.41, sa.4, ss.225-235, 2024 (SCI-Expanded, Scopus, TRDizin)

35. An effective treatment in Erdheim Chester disease: vemurafenib: a case report

Bozan E., Darçın T., Yaman S., YİĞENOĞLU T. N., KIZIL ÇAKAR M., DAL M. S., et al.

Journal of Medical Case Reports , cilt.17, sa.1, 2023 (ESCI, Scopus)

36. International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report

Özatlı D., Giden A. O., ERKURT M. A., KORKMAZ S., BAŞCI S., Ulas T., et al.

Transfusion and Apheresis Science , cilt.62, sa.2, 2023 (SCI-Expanded, Scopus)

37. Gene therapy approaches for sickle cell anemia

Ulas T., DAL M. S.

Transfusion and Apheresis Science , cilt.62, sa.2, 2023 (SCI-Expanded, Scopus)

38. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

DAL M. S., Ulu B. U., UZAY A., Akay O. M., BEŞIŞIK S., Yenerel M. N., et al.

Annals of Hematology , cilt.102, sa.1, ss.133-140, 2023 (SCI-Expanded, Scopus)

39. Latent tuberculosis in adult hematopoietic stem cell transplantation recipients: Clinical experience from a previously endemic population

MERT D., Ozer M., Merdin A., İSKENDER G., Uncu Ulu B., KIZIL ÇAKAR M., et al.

Medicine (United States) , cilt.101, sa.46, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

40. Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities

Aslan Candır B., YİĞENOĞLU T. N., KIZIL ÇAKAR M., DAL M. S., ALTUNTAŞ F.

Journal of Oncology Pharmacy Practice , cilt.28, sa.4, ss.972-974, 2022 (SCI-Expanded, Scopus)

41. Could blood groups have prognostic significance on survival in patients with diffuse large B cell lymphoma?

Ulu B. U., BAŞCI S., Bakırtaş M., YİĞENOĞLU T. N., BATGİ H., YILDIZ J., et al.

Leukemia Research , cilt.115, 2022 (SCI-Expanded, Scopus)

42. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Akpinar S., Dogu M. H., ÇELİK S., Ekinci O., Hindilerden I. Y., DAL M. S., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.22, sa.3, ss.169-173, 2022 (SCI-Expanded, Scopus)

43. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies

Yaman S., BAŞCI S., Turan G., Ulu B. U., YİĞENOĞLU T. N., DAL M. S., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.22, sa.2, 2022 (SCI-Expanded, Scopus)

44. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

BAŞCI S., ATA N., ALTUNTAŞ F., YİĞENOĞLU T. N., DAL M. S., KORKMAZ S., et al.

Internal and Emergency Medicine , cilt.17, sa.1, ss.135-139, 2022 (SCI-Expanded, Scopus)

45. Febrile neutropenia risk factors in actively treated diffuse large B-cell lymphoma patients

Bakirtas M., YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Yaman S., KIZIL ÇAKAR M., et al.

Iraqi Journal of Hematology , cilt.11, sa.1, ss.7-12, 2022 (Scopus)

46. Face masks and polycythemia is the standard hemoglobin cutoff valid in the pandemic?

Yaman S., BAŞCI S., Turan G., Ulu B. U., YİĞENOĞLU T. N., Bahsi T., et al.

Iraqi Journal of Hematology , cilt.11, sa.2, ss.130-133, 2022 (Scopus)

47. Efficiency of intravenous iron carboxymaltose in patients with iron-deficiency anemia due to heavy menstrual bleeding: a single-center experience

Seçilmiş S., İSKENDER D., Candir B., Bozan E., Yaman S., Ulu B., et al.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.10, ss.3487-3492, 2022 (SCI-Expanded, Scopus)

48. The clinicopathological features and survival of Castleman disease: A multicenter Turkish study

Yildiz J., Bagci M., Sayin S., Kaya A., YILMAZ F. H., EKİNCİ O., et al.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.4, ss.1131-1137, 2022 (SCI-Expanded, Scopus)

49. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

Uncu Ulu B., DAL M. S., Yönal Hindilerden İ., Akay O. M., MEHTAP Ö., BÜYÜKKURT N., et al.

Journal of Chemotherapy , cilt.34, sa.3, ss.190-198, 2022 (SCI-Expanded, Scopus)

50. Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients

YİĞENOĞLU T. N., BAŞCI S., Şahin D., Ulaş T., DAL M. S., KORKMAZ S., et al.

Transfusion and Apheresis Science , cilt.60, sa.6, 2021 (SCI-Expanded, Scopus)

51. Does myeloma genetic have an effect on stem cell mobilization?

BAŞCI S., YİĞENOĞLU T. N., Yaman S., Bozan E., Ulu B. U., Bakırtaş M., et al.

Transfusion and Apheresis Science , cilt.60, sa.6, 2021 (SCI-Expanded, Scopus)

52. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with relapsed or refractory germ cell tumors

YILDIZ J., Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Bakirtas M., Sahin D., et al.

Journal of B.U.ON. , cilt.26, sa.6, ss.2531-2536, 2021 (SCI-Expanded, Scopus)

53. Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma

Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Bakırtaş M., Şahin D., Darçın T., et al.

Leukemia Research , cilt.110, 2021 (SCI-Expanded, Scopus)

54. Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study

Merdin A., DAL M. S., KIZIL ÇAKAR M., Bahsi T., Düzkale N., YILDIZ J., et al.

Medicine (United States) , cilt.100, sa.41, 2021 (SCI-Expanded, Scopus)

55. Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experience

BATGİ H., DAL M. S., ERKURT M. A., KUKU İ., KURTOĞLU E., Hindilerden I. Y., et al.

Transfusion and Apheresis Science , cilt.60, sa.5, 2021 (SCI-Expanded, Scopus)

56. Extracorporeal photopheresis in steroid-refractory chronic graft-versus-host disease: A retrospective multicenter study

DAL M. S., BATGİ H., ERKURT M. A., Hindilerden I. Y., KUKU İ., KURTOĞLU E., et al.

Transfusion and Apheresis Science , cilt.60, sa.5, 2021 (SCI-Expanded, Scopus)

57. Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey

Kalpakci Y., Hacibekiroglu T., Darcin T., AkgunCagliyan G., KIZIL ÇAKAR M., Hacioglu S. K., et al.

Transfusion and Apheresis Science , cilt.60, sa.5, 2021 (SCI-Expanded, Scopus)

58. Apheresis in patients with sepsis: A multicenter retrospective study

Aydin K., KORKMAZ S., ERKURT M. A., SARICI A., Ekinci O., Baysal N. A., et al.

Transfusion and Apheresis Science , cilt.60, sa.5, 2021 (SCI-Expanded, Scopus)

59. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center

Secilmis S., DAL M. S., KIZIL ÇAKAR M., Merdin A., Baysal N. A., ALTUNTAŞ F.

Journal of B.U.ON. , cilt.26, sa.5, ss.2026-2032, 2021 (SCI-Expanded, Scopus)

60. Recovery of Symmetrical Peripheral Gangrene of Limbs in a Patient After Performing Hemoadsorption in Septic Shock

Uncu Ulu B., YİĞENOĞLU T. N., Hacıbekiroğlu T., Sağlam D. A., Kılınç A., İSKENDER G., et al.

Journal of Clinical Apheresis , cilt.36, sa.4, ss.649-653, 2021 (SCI-Expanded, Scopus)

61. Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin’s lymphoma

MERT D., Merdin A., ÇEKEN S., DAL M. S., ERTEK M., ALTUNTAŞ F.

Journal of Cancer Research and Therapeutics , cilt.17, sa.4, ss.951-955, 2021 (SCI-Expanded, Scopus)

62. Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey

DAL M. S., Merdin A., ERKURT M. A., Ekinci Ö., ALBAYRAK M., Hacıoglu S. K., et al.

Journal of B.U.ON. , cilt.26, sa.4, ss.1536-1539, 2021 (SCI-Expanded, Scopus)

63. Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience

Goren Sahin D., Akay O. M., KEKLİK M., Okan V., Karakus A., DEMİR C., et al.

Annals of Hematology , cilt.100, sa.7, ss.1667-1675, 2021 (SCI-Expanded, Scopus)

64. COVID-19 in hematopoietic cell transplant recipients

ALTUNTAŞ F., ATA N., YİĞENOĞLU T. N., BAŞCI S., DAL M. S., KORKMAZ S., et al.

Bone Marrow Transplantation , cilt.56, sa.4, ss.952-955, 2021 (SCI-Expanded, Scopus)

65. The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?

BAŞCI S., YİĞENOĞLU T. N., Bakırtaş M., Uncu Ulu B., Yaman S., DAL M. S., et al.

Leukemia Research , cilt.102, 2021 (SCI-Expanded, Scopus)

66. Convalescent plasma therapy in patients with COVID-19

ALTUNTAŞ F., YİĞENOĞLU T. N., BAŞCI S., DAL M. S., KORKMAZ S., Turgut B., et al.

Transfusion and Apheresis Science , cilt.60, sa.1, 2021 (SCI-Expanded, Scopus)

67. Old is bad? The effect of age on peripheral stem cell mobilization and transplantation outcomes

BAŞCI S., Bakırtaş M., Uncu Ulu B., YİĞENOĞLU T. N., Yaman S., BATGİ H., et al.

Transfusion and Apheresis Science , cilt.60, sa.1, 2021 (SCI-Expanded, Scopus)

68. The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience

BATGİ H., Merdin A., DAL M. S., KIZIL ÇAKAR M., YILDIZ J., BAŞCI S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.8, ss.1857-1863, 2020 (SCI-Expanded, Scopus)

69. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

BAŞCI S., ATA N., ALTUNTAŞ F., YİĞENOĞLU T. N., DAL M. S., KORKMAZ S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1676-1682, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

70. A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report

BATGİ H., DAL M. S., Merdin A., KIZIL ÇAKAR M., YİĞENOĞLU T. N., ALTUNTAŞ F.

Journal of Oncology Pharmacy Practice , cilt.26, sa.6, ss.1499-1500, 2020 (SCI-Expanded, Scopus)

71. Evaluation of HBV, HCV, and HIV seroprevalence in patients with plasma cell disorders

MERT D., Merdin A., KIZIL ÇAKAR M., DAL M. S., ALTUNTAŞ F.

Medicine (United States) , cilt.99, sa.34, 2020 (SCI-Expanded, Scopus)

72. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption

YİĞENOĞLU T. N., Ulas T., DAL M. S., KORKMAZ S., ERKURT M. A., ALTUNTAŞ F.

Transfusion and Apheresis Science , cilt.59, sa.4, 2020 (SCI-Expanded, Scopus)

73. Inferior prognosis in poor mobilizing myeloma patients

YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Bakırtaş M., Kılınç A., Şahin D., et al.

Transfusion and Apheresis Science , cilt.59, sa.3, 2020 (SCI-Expanded, Scopus)

74. The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors

YİĞENOĞLU T. N., BAŞCI S., Bakırtaş M., Ulu B. U., Kılınç A., Şahin D., et al.

Transfusion and Apheresis Science , cilt.59, sa.3, 2020 (SCI-Expanded, Scopus)

75. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor

Merdin A., KIZIL ÇAKAR M., DAL M. S., MERT D., YILDIZ J., BAŞCI S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.4, ss.929-932, 2020 (SCI-Expanded, Scopus)

76. The Outcome of Autologous Stem Cell Transplantation in Adolescent and Young Adult Patients with Multiple Myeloma

YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Bakirtas M., Sahin D., Darcin T., et al.

Eurasian Journal of Medicine and Oncology , cilt.4, sa.1, ss.79-83, 2020 (ESCI, Scopus, TRDizin)

77. Evaluation of clinical outcome and mixed chimerism follow-up after allogeneic hematopoietic stem cell transplantation in hematological malignancies

Bahsi T., YİĞENOĞLU T. N., ERDEM H. B., KIZIL ÇAKAR M., DAL M. S., ALTUNTAŞ F.

Gazi Medical Journal , cilt.31, sa.1, ss.52-55, 2020 (ESCI, Scopus)

78. Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations

Merdin A., DAL M. S., KIZIL ÇAKAR M., YILDIZ J., Ulu B. U., BATGİ H., et al.

Medicine (United States) , cilt.99, sa.14, 2020 (SCI-Expanded, Scopus)

79. Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

NAMDAROĞLU S., Kaya A. H., BATGİ H., Kayikci O., DAL M. S., İSKENDER D., et al.

Scientific Reports , cilt.9, sa.1, 2019 (SCI-Expanded, Scopus)

80. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment

Merdin A., İSKENDER D., Ulu B. U., Doğan M., KIZIL ÇAKAR M., DAL M. S., et al.

Medicine , cilt.98, sa.30, 2019 (SCI-Expanded, Scopus)

81. Agreement between QuantiFERON-TB gold in-tube and tuberculin skin tests in hematopoietic stem cell transplantation candidates Hematopoetik Kök Hücre Nakli Adaylarında QuantiFERON-TB Gold In-tube ve Tüberkülin Deri Testi Arasındaki Uyum

Yapar Toros G., ÇEKEN S., Sezen F., GEDİK H., DAL M. S., ERTEK M., et al.

Mediterranean Journal of Infection, Microbes and Antimicrobials , cilt.8, 2019 (Scopus)

82. The Turkish experience with therapeutic plasma exchange: A national survey

KORKMAZ S., Solmaz Medeni S., Demirkan F., BEŞIŞIK S., Altay Dadin S., Akgun Cagliyan G., et al.

Transfusion and Apheresis Science , cilt.58, sa.3, ss.287-292, 2019 (SCI-Expanded, Scopus)

83. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy

Kaya A. H., Tekgündüz E., İLKKILIÇ K., Dal M. S., Merdin A., Karakus A., et al.

Journal of Chemotherapy , cilt.30, sa.1, ss.44-48, 2018 (SCI-Expanded, Scopus)

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Proje

Tez Danışmanlığı

Açık Erişim